Tactile Systems Technology, Inc. (TCMD)
Healthcare
- Fundamental
- 4
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3); the strategy requires qualitativeScore ≥ 3 before any bullish entry, and no chart pattern overrides the upstream qualitative screen.
Company overview
Tactile Systems Technology, Inc. develops and provides medical devices for chronic diseases in the United States. Its products include the Flexitouch Plus system for lymphedema treatment, the Entre system for at-home venous disorder treatment, and the AffloVest for pulmonary secretion management. The company is headquartered in Minneapolis, Minnesota.
Fundamental
goodTCMD exhibits strong liquidity and growth with reasonable valuation, but moderate profitability and reimbursement risks limit its fundamental score to 4/5.
Strong liquidity and improving growth/margins with net-cash leverage; valuation looks attractive on EV multiples and DCF, but reimbursement/Medicare-policy risk and only moderate profitability keep the score at 4/5.
Sentiment
weakInstitutional accumulation and a moderate buy consensus support sentiment, but no immediate catalysts or retail interest are present.
No actionable catalyst exists in the 1–30 trading-day window: the Q2 2026 beat with share-repurchase authorization (2026-08-10, announced, rewarded by coverage at +0.45) and the ElastiMed MyoSleeve distribution deal (2026-07-13) are both digested, and no forward-dated event is announced. Media sentiment is determinate and stable-positive — institutional accumulation (BlackRock, Man Group, BNY Mellon) and a Moderate Buy consensus with a $38.40 average target — but the delta is essentially flat, no in-window event is demonstrably market-rewarded, and retail chatter is absent; the Red-Flag Screen is clean with no cap applied, leaving an Absent setup on an empty forward calendar.
Technical
weakThe stock shows short-term stabilization within a downtrend, with technical indicators suggesting a bounce-only scenario.
TCMD (22.57) sits below its SMA20 (22.83), SMA50 (25.98), SMA200 (26.84) and EMA21 (23.24), only modestly above the EMA9 (22.46) — the intermediate and primary trends remain down after the early-August post-earnings slide from ~$30. Short-term stabilization is emerging: MACD line is still negative (-1.01) but the histogram is positive and expanding (0.18) after a 09-09 bullish crossover, RSI has recovered from ~28 to 38.34, Williams %R has climbed from -97 to -47, and daily lows have been rising (21.29 → 22.00 → 22.31). ADX 30.37 signals a strong trend, but that trend is DOWN, so the read is capped at bounce-only quality: technicalScore 2. Independently of chart quality, the trade is hard-blocked by the qualitative override (qualitativeScore 2 < 3).
You’re looking at 2026-09-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.